Related references
Note: Only part of the references are listed.Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
Kensei Yamaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study
Jingyuan Wang et al.
LANCET ONCOLOGY (2023)
Clinical application and detection techniques of liquid biopsy in gastric cancer
Shuo Ma et al.
Molecular Cancer (2023)
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
Y. Kubota et al.
ESMO OPEN (2023)
Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
Rui-hua Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial
Kohei Shitara et al.
LANCET (2023)
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Nina E. Weisser et al.
NATURE COMMUNICATIONS (2023)
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
Vincenza Caputo et al.
Exploration of Targeted Antitumor Therapy (2023)
Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Joseph J. Zhao et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara et al.
NATURE (2022)
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam et al.
LANCET ONCOLOGY (2022)
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
R. Obermannova et al.
ANNALS OF ONCOLOGY (2022)
Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101).
Elizabeth Catherine Smyth et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Gastric cancer and genomics: review of literature
Takumi Onoyama et al.
JOURNAL OF GASTROENTEROLOGY (2022)
HERIZON-GEA-01: Zanidatamab plus chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Josep Tabernero et al.
FUTURE ONCOLOGY (2022)
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT) : a randomised, double-blind, placebo-controlled, phase 2 study
Zev A. Wainberg et al.
LANCET ONCOLOGY (2022)
Association of PD-L1 Expression and OtherVariables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials
Harry H. Yoon et al.
JAMA ONCOLOGY (2022)
A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines
Sang Soo Eom et al.
JOURNAL OF GASTRIC CANCER (2022)
Association of PD-L1 Expression and OtherVariables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials
Harry H. Yoon et al.
JAMA ONCOLOGY (2022)
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2021)
Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Regulation of PD-L1 expression in the tumor microenvironment
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
U. Sahin et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Jayson L. Parker et al.
CANCER MEDICINE (2021)
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
F. Pietrantonio et al.
ESMO OPEN (2021)
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
Antonio Pellino et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Yoshiaki Nakamura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer
Yukiya Narita et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
K. Shitara et al.
ANNALS OF ONCOLOGY (2021)
Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
S-E. Al-Batran et al.
ANNALS OF ONCOLOGY (2021)
HER2-targeted therapies in gastric cancer
Yinxing Zhu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Michael L. Cheng et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Microsatellite instability: a review of what the oncologist should know
Kai Li et al.
CANCER CELL INTERNATIONAL (2020)
High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers
Joon Young Hur et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
Seiichiro Mitani et al.
CANCERS (2020)
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas
S. Derks et al.
ANNALS OF ONCOLOGY (2020)
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
Yujun Park et al.
CANCER RESEARCH AND TREATMENT (2020)
Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections
Min Ye et al.
CANCER CELL INTERNATIONAL (2020)
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
Akitaka Makiyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
Do-Youn Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer
Jian Yang et al.
CELL DEATH & DISEASE (2020)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y. Janjigian et al.
LANCET ONCOLOGY (2020)
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial
Daniel V. T. Catenacci et al.
LANCET ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura et al.
NATURE MEDICINE (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Dan Sha et al.
CANCER DISCOVERY (2020)
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
De-Shen Wang et al.
GUT (2019)
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1
Lola Fashoyin-Aje et al.
ONCOLOGIST (2019)
New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology
Perrine Janiaud et al.
CANCER TREATMENT REVIEWS (2019)
MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).
Filippo Pietrantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design
Daniel V. T. Catenacci et al.
FUTURE ONCOLOGY (2019)
Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing A Direct Comparison Study with Immunohistochemistry
Sangjoon Choi et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
O. Tuereci et al.
ANNALS OF ONCOLOGY (2019)
Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?
Kohei Yamashita et al.
BRITISH JOURNAL OF CANCER (2019)
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Steven B. Maron et al.
CLINICAL CANCER RESEARCH (2019)
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Ken Masuda et al.
BMC CANCER (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis
Hyeong Su Kim et al.
JOURNAL OF CANCER (2019)
Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond
Mykola Zubarayev et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN gamma secretion
Bharat K. R. Chaganty et al.
CANCER LETTERS (2018)
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer
Takahiro Yoshioka et al.
CANCER SCIENCE (2018)
Proposed Molecular and miRNA Classification of Gastric Cancer
Lara Alessandrini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
DNA mismatch repair in cancer
Marina Baretti et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Elizabeth D. Thompson et al.
GUT (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization
Micaela Mathiak et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
Mismatch Repair Deficiency, Microsatellite Instability, and Survival An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial
Elizabeth C. Smyth et al.
JAMA ONCOLOGY (2017)
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Angela N. Bartley et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project
Bo Hwa Sohn et al.
CLINICAL CANCER RESEARCH (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
F. Pietrantonio et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
Soomin Ahn et al.
MODERN PATHOLOGY (2016)
HER2 testing in gastric cancer: An update
Lucas Faria Abrahao-Machado et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Christine Boeger et al.
ONCOTARGET (2016)
High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis
Dan Wang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2016)
Oncogenic HER2 fusions in gastric cancer
De-Hua Yu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
Sangjeong Ahn et al.
ONCOTARGET (2015)
Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer
Therese Phillips et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
X. Su et al.
BRITISH JOURNAL OF CANCER (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker
Masahiro Hirakawa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
Kohei Shitara et al.
GASTRIC CANCER (2013)
Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas
Eun Yoon Cho et al.
MODERN PATHOLOGY (2013)
Microsatellite Instability Status in Gastric Cancer: A Reappraisal of Its Clinical Significance and Relationship with Mucin Phenotypes
Joo-Yeun Kim et al.
KOREAN JOURNAL OF PATHOLOGY (2013)
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
Y. Y. Janjigian et al.
ANNALS OF ONCOLOGY (2012)
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
Niantao Deng et al.
GUT (2012)
HER2 testing in gastric cancer: a practical approach
Josef Rueschoff et al.
MODERN PATHOLOGY (2012)
Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas
Eun Yoon Cho et al.
PATHOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays
Kab Choong Kim et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy
K. R. Fareed et al.
BRITISH JOURNAL OF CANCER (2010)
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
Janet E. Dancey et al.
CLINICAL CANCER RESEARCH (2010)
Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk
Lydia E. Wroblewski et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Microsatellite instability in colorectal cancer-the stable evidence
Eduardo Vilar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
J. Wei et al.
BRITISH JOURNAL OF CANCER (2008)
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
Ugur Sahin et al.
CLINICAL CANCER RESEARCH (2008)
Claudin proteins in human cancer: Promising new targets for diagnosis and therapy
PJ Morin
CANCER RESEARCH (2005)
Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients
R Napieralski et al.
CLINICAL CANCER RESEARCH (2005)
Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells
WG Wang et al.
CANCER RESEARCH (2004)
claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing
T Niimi et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
